Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.57 |
| ▸ | C3AR1 | Q16581 | 7/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788471 | 1.00 | FOLH1 (0.57) | FOLH1C3AR1GID4F7CHRM2 | |
| SCHEMBL7786281 | 0.89 | FOLH1 (0.43) | FOLH1C3AR1 | |
| SCHEMBL7785788 | 0.89 | FOLH1 (0.43) | FOLH1C3AR1 | |
| SCHEMBL7786368 | 0.89 | FOLH1 (0.49) | FOLH1C3AR1 | |
| SCHEMBL7786354 | 0.89 | FOLH1 (0.49) | FOLH1C3AR1 | |
| SCHEMBL7786343 | 0.87 | FOLH1 (0.43) | FOLH1C3AR1F7 | |
| SCHEMBL7786351 | 0.87 | FOLH1 (0.43) | FOLH1C3AR1F7 | |
| SCHEMBL7788448 | 0.86 | C3AR1 (0.44) | FOLH1C3AR1 | |
| SCHEMBL7788437 | 0.86 | C3AR1 (0.44) | FOLH1C3AR1 | |
| SCHEMBL4738184 | 0.84 | FOLH1 (0.62) | FOLH1C3AR1GID4CHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | LEE DENNIS (US) | 2001-12-27 | — | — | US | claimed |
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | claimed |
| US-20010056185-A1 | C3A receptor ligands | LEE DENNIS (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | C3AR1, C5AR1, C5AR2 | FOLH1 1373/4885C3AR1 1/4885GID4 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.